Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
April 27, 2023
Earnings Call Speaker Segments
Peter Dannenbaum
executiveThanks. Morning, everyone. Glad to have you on Merck's Q1 2023 earnings call. On the line today are Rob Davis, our Chairman and Chief Executive Officer, Caroline Litchfield, our Chief Financial Officer, and Dr. Dean Li, President of Merck Research Laboratories. Before we dive in, a few quick notes. In our GAAP results, you'll notice certain items, including acquisition-related charges, restructuring costs, and some other things. Those have been left out of our non-GAAP results, and you can find a reconciliation in the press release. Also, please be aware that certain remarks we're making today could be viewed as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These remarks reflect Merck management's present beliefs and carry significant risks and uncertainties. Should our underlying assumptions turn out to be wrong or uncertainties come to pass, actual results could differ materially from what those forward-looking statements set forth. Our SEC filings, including Item 1A in the 2022 10-K, lay out certain risk factors and cautionary statements that might cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. A slide presentation will run alongside our speakers' prepared remarks on today's call; those slides, together with the earnings release, today's prepared remarks, and our SEC filings, are all available in the investor relations section of Merck's website. With that, let me hand things over to Rob.
Robert Davis
executiveThank you, Peter. Good morning, and I appreciate everyone joining us today. We kicked off 2023 with meaningful progress in crucial pipeline areas, alongside ongoing robust results from our main growth engines. I continue to feel great about how consistently and excellently our team executes, and I'm sure our approach is paving the way toward lasting achievement; we stay anchored in our collective mission to advance courageous science that provides answers for significant unmet medical needs and, crucially, preserves and enhances lives globally. Our focuses haven't changed. Through prioritizing our science-driven approach, we plan to deliver key breakthroughs from our in-house discovery efforts and through strategic business deals aimed at securing the most exciting and synergistic outside science, utilizing our top-tier clinical development strengths; we seek to maintain pipeline momentum throughout 2023 and afterward, and we're certain this will drive robust commercial and financial results, plus long-term value generation for patients and investors. Regarding securing key outside innovation, we're delighted about our declared purchase of Prometheus Biosciences. Prometheus provides us with a possible top-tier innovative therapy that might revolutionize standard care for those battling ulcerative colitis and Crohn's disease, which can be devastating conditions, along with an expanded pipeline and a tech platform supporting a precision medicine strategy. It speeds up our footprint in immunology, broadens our pipeline's variety, and delivers a potentially major revenue growth engine over the coming decade. This deal also marks yet another instance of Merck moving boldly when science and worth intersect. Now shifting to our Q1 outcomes. We achieved substantial fundamental growth, once you exclude the anticipated year-over-year drop in LAGEVRIO revenue. This shows ongoing core vigor and momentum in our main growth engines, especially oncology and vaccines; these outcomes bolster our assurance in the solid need for our cutting-edge portfolio and in our projection for the rest of 2023, which Caroline will address shortly. Turning to our research group, we've achieved notable progress; in cardiovascular, we presented the outstanding efforts of our research team at the American College of Cardiology Conference in March. The robustness of the findings from the phase III STELLAR trial on sotatercept for pulmonary arterial hypertension strengthens our conviction in this vital novel mechanism's capacity to alter the treatment approach for patients. Furthermore, striking outcomes from the phase II study on our oral PCSK9 inhibitor indicate this might become a globally available therapeutic choice for those requiring LDL cholesterol lowering. The wins we're seeing throughout our cardiovascular pipeline have sparked enthusiasm company-wide and a conviction that Merck will continue its proud history of delivering pioneering treatments to aid patients with cardiovascular disease. And that these initiatives will add substantially to our growth over the long haul. When it comes to oncology, we were glad to report the favorable top-line data from KEYNOTE-671, demonstrating a meaningful gain in event-free survival among particular individuals with early-stage non-small cell lung cancer, and we anticipate a possible approval before this year ends. Together with our collaborator, Moderna, we're moving quickly to broaden our research on pairing KEYTRUDA with an individualized neoantigen therapy — what we used to call a personalized cancer vaccine therapy — in adjuvant melanoma as well as possible other tumor types. The considerable headway we've achieved throughout our extensive pipeline gives me a lot of encouragement. Right now we're pursuing a larger count of late-stage programs spanning more therapeutic areas and modalities than we have at any point in recent years. To sum up, we've kicked off 2023 with momentum on the scientific, commercial, and operational fronts, and we anticipate robust growth for the entire year in both our human and animal health segments. The strides we've taken make me proud, yet as ever, I know we must act swiftly and urgently to accomplish still more. My gratitude goes out to our worldwide team for their unwavering commitment as we construct a sustainable innovation engine that will generate value for patients and shareholders far into the coming decade. Having said that, I'll hand the call over to Caroline.
Caroline Litchfield
executiveThank you, Rob, and good morning. As Rob mentioned, we are off to a strong start to the year, with robust underlying performance across our key growth drivers. These results demonstrate further that placing science and innovation at the core of our strategy is delivering returns. What we've achieved is thanks to excellent execution by our team of dedicated colleagues, who bring our essential medicines and vaccines to people and animals around the globe. We remain very confident in our ability to continue delivering in the near term as we invest prudently to maximize long-term value for patients and shareholders. Other income was $17 million. Now let's turn to our first quarter results. Companywide revenues totaled $14.5 billion. Excluding the impact of LAGEVRIO and foreign exchange, the business delivered very strong underlying growth of 15%. All my remaining revenue comments will be on an ex exchange basis. Our human health business sustained its strong momentum. Excluding LAGEVRIO, growth was 18%, driven by oncology and vaccines. Our animal health business also delivered solid performance, with sales rising 5%, supported by gains in both livestock and companion animal products. Now to how our key brands did in the first quarter. In oncology, KEYTRUDA grew 24% to $5.8 billion, driven by strong global demand for metastatic indications, plus increased utilization from approvals in early-stage cancers. In the U.S., KEYTRUDA progressed across every major tumor type and continues to benefit from uptake in earlier stage cancers, including Triple-Negative Breast Cancer, as well as certain types of renal cell carcinoma and melanoma. We continue to expect gradual uptake from KEYNOTE-091 in earlier stage lung cancer, as we work with the medical community to increase adjuvant treatment rates among diagnosed patients who undergo surgery; we, along with others, are also working to improve the low level of lung cancer screenings and follow-up through diagnosis, which we expect to increase over time. The positive feedback we've received thus far is encouraging. We're excited about the potential to provide patients an additional treatment option following the positive results of the KEYNOTE-671 study. Together, these studies leave us well positioned to extend our leadership in non-small cell lung cancer. We also look forward to offering certain adult patients with bladder cancer a new treatment option following the recent approval of KEYNOTE-869. Outside the U.S., KEYTRUDA continues to hold its leadership in non-small cell lung cancer. Growth came from uptake in metastatic renal cell carcinoma and certain types of head and neck cancer, and in earlier stage cancers as well, including certain types of high risk early stage Triple-Negative Breast Cancer, which continues to launch in additional markets. LYNPARZA remains the market-leading PARP inhibitor. Alliance revenue rose 8%, primarily on higher demand in key European markets among certain patients with ovarian cancer. LENVIMA Alliance revenue increased 5% on greater uptake in treating certain patients with advanced renal cell carcinoma in key European markets. Our vaccines portfolio delivered outstanding growth, led by GARDASIL, which increased 43% to $2 billion. Those results showed strong demand in important markets abroad, particularly China, plus more supply. Growth also got a lift because we moved certain shipments into China from the back half to the front half of the year, which let us have product on hand to meet higher demand following GARDASIL 9's approval for a broader indication covering females and males ages 9 through 45. Vaccine revenue also benefited from increased demand for VAXNEUVANCE during the continuing pediatric rollout, above all in the U.S.; in our hospital acute care portfolio, BRIDION sales climbed 27%, helped by a larger share of the neuromuscular blockade reversal agent market. Animal health delivered another strong quarter, with sales rising 5%, driven by solid demand across our livestock lineup, particularly ruminant and poultry items, as well as deliberate pricing moves. Let me walk you through the remaining P&L items, and everything I say will be non-GAAP. Gross margin reached 76.9%, an increase of 6.1 percentage points thanks to favorable product mix, which captures a gain from reduced LAGEVRIO sales. Operating expenses climbed to $6.7 billion, which includes $1.4 billion of charges from the Imago acquisition and our licensing and collaboration deal with Kelun-Bio. Without those charges, operating expenses grew 12%, reflecting larger investments behind our main growth drivers and pipeline. Other income came to $70 million, and our tax rate was 20.4%, reflecting the adverse effect of the Imago transaction, on which no tax benefit was recorded. In total, we earned $1.40 per share, a figure that includes a $0.52 hit from charges related to the Imago acquisition and our Kelun-Bio agreement. Turning now to our 2023 non-GAAP guidance: the business's sustained operational momentum allows us to raise and narrow our revenue outlook for the full year. We now anticipate revenue of $57.7 billion-$58.9 billion, with approximately $1 billion of that from LAGEVRIO. We expect solid underlying revenue growth of 8%-10%, offset by the LAGEVRIO decrease and a negative foreign exchange impact of about 2 percentage points at mid-April rates. Our growth margin is still projected at roughly 77%. We have narrowed the operating expense range to $23.3 billion-$24.1 billion. Keep in mind that this range contains $1.4 billion of upfront R&D expenses tied to the Imago acquisition and our Kelun-Bio agreement. The guidance assumes neither the proposed Prometheus acquisition nor any other significant potential business development deals. Other income should be about $250 million. We still assume a full year tax rate of 17%-18% and roughly 2.55 billion shares outstanding. In sum, we are raising and narrowing our expected EPS range to $6.88-$7.00. That outlook incorporates an FX headwind of about 4 percentage points, using mid-April rates. One point to note: the guidance leaves out any impact from the planned Prometheus purchase, which we expect to close in Q3 of this year. That deal is going to result in a one-time charge, which adds roughly $10.3 billion to R&D expense — that works out to about $4 for each share. This charge is going to appear in both our GAAP and non-GAAP figures. On top of that, ongoing investment to advance pipeline assets, along with financing costs, ought to reduce EPS by approximately $0.25 over the initial 12 months following close. Other income came in at $17 million. As Rob mentioned, the science behind Prometheus is compelling, and we're truly excited — we think this acquisition can bring substantial value to patients and shareholders alike. Our guidance reflects the continued confidence we hold in the fundamental strength of the business, driven by our core pillars: oncology, vaccines, and animal health. A few points to keep in mind while building your models: here in the U.S., KEYTRUDA has delivered impressive growth over the past several quarters, driven by recent launches, particularly in early-stage indications such as Triple-Negative Breast Cancer. We continue to expect those earlier-stage indications to fuel growth, but the year-over-year rate ought to moderate as we lap their exceptionally strong initial uptake. Outside the U.S., we continue to expect strong volume growth for KEYTRUDA. That said, pricing pressure is building, particularly as we introduce new indications in major European markets, which is going to restrain ex-U.S. growth. Finally, we're well positioned to protect many more people from HPV-related cancers both today and well into the future. With demand for the vaccine running high across the world, we expect GARDASIL growth to accelerate for the full year 2023 relative to 2022, though it won't quite equal the pace we saw this quarter. Now on capital allocation — following the announcement of the Prometheus acquisition, we remain committed to our priorities; we'll continue to place investment first in our business and in expanding the pipeline so we can capture the value of the many near- and long-term opportunities ahead of us. Our dividend commitment remains, and we intend to increase it over time. Business development is still a top priority, and our solid investment-grade credit rating gives us room to pursue further science-driven, value-enhancing deals down the road. We'll also conduct a modest amount of share repurchases during this year. To close, we have strong confidence in our business outlook, driven by worldwide demand for our innovative medicines and vaccines. We possess both financial and operational strength, and by continuing to execute at a high level, we'll keep delivering value to patients and shareholders far into the future. With that, I'll turn the call over to Dean.
Dean Li
executiveThanks, Caroline. Greetings, everybody. I'll share a few key developments that have occurred since our previous earnings call, beginning with what we've achieved in cardiovascular disease, then oncology, then infectious disease, and after that immunology, together with the acquisition of Prometheus we announced not long ago. As Rob said before, at the American College of Cardiology, held alongside the World Congress of Cardiology meeting in New Orleans, we presented results from the phase III STELLAR trial, which evaluated sotatercept for pulmonary arterial hypertension, along with data from the phase II-B trial of our oral PCSK9 inhibitor candidate MK-0616, being developed to treat hypercholesterolemia. In STELLAR, sotatercept plus stable background therapy hit its primary endpoint, delivering a substantial gain in six-minute walk distance at 24 weeks versus placebo plus background therapy. Eight of nine secondary measures were also met, among them a compelling decrease in time to clinical worsening or death relative to placebo. Those findings came out at the same time in the New England Journal of Medicine. We're working hard to submit filings based on the STELLAR data to regulatory agencies, and right now we expect to file in the U.S. during the third quarter of this year, with the EU to follow. The sotatercept program is moving ahead on a wide front, and every one of its studies — Hyperion, Zenith, SOTERIA, and the phase II Cadence trial — is currently enrolling participants. In addition, at the ACC meeting, comprehensive phase II-B data on MK-0616 were shared, demonstrating LDL cholesterol decreases ranging from 41.2% to 60.9% relative to placebo. Among those in the study receiving MK-0616 at its highest dose, 90% succeeded in hitting their LDL-C target. Broad worldwide access could become possible through an oral PCSK9 inhibitor. We are initiating multiple phase III trials spanning secondary prevention, primary prevention for intermediate- to high-risk individuals, and heterozygous familial hypercholesterolemia patients. Simultaneously, a cardiovascular outcomes trial will be conducted. We're getting closer to our goal of creating medications that enhance and prolong the lives of people dealing with cardiovascular conditions, and we're eager to provide further news in the future. Turning now to oncology. As I've mentioned previously, one of our main areas of concentration and a top execution priority has involved creating therapies for cancer at its earliest phases, where a substantial unmet need still exists. We shared that the FDA has accepted our filing for KEYTRUDA alongside platinum doublet chemotherapy used as neoadjuvant treatment, then adjuvant therapy afterward, for patients whose stage II, III-A, and III-B non-small cell lung cancer can be surgically removed, drawing on results so far from the KEYNOTE-671 trial. The PDUFA action date for the agency is set for October 16th. Findings in detail will be shared at ASCO this coming June. Along with KEYTRUDA's approval for the adjuvant treatment of specific non-small cell lung cancer patients, which was based on KEYNOTE-091, we now have the KEYNOTE-671 trial adding to the extensive body of data we've produced. Among the pertinent ongoing research efforts are KEYNOTE-867 and KEYLYNK-012. This broad development initiative highlights our dedication to a field where there's considerable room to enhance patient outcomes. Furthermore, it brings attention to how essential early detection of lung cancer through screening truly is. During the AACR annual meeting, we collaborated with Moderna to share comprehensive findings from KEYNOTE-942. In that phase II-B trial, researchers looked at giving KEYTRUDA alongside V940—which is also called mRNA-4157, a tailored neoantigen therapy administered as adjuvant treatment—to individuals with stage III and IV melanoma who had been fully resected and faced a high chance of the disease returning. What these findings show, for the first time, is better recurrence-free survival relative to PD1 blockade, which is the adjuvant standard of care today, within this resected high-risk melanoma group. They also offer the earliest randomized proof that a personalized neoantigen therapy may deliver a potential advantage. This combo has received breakthrough therapy designation from the FDA, and for patients whose high-risk stage III and IV melanoma has been completely resected, the European Medicines Agency has granted prime designation. The plan from Merck and Moderna is to begin a phase III study in adjuvant melanoma at some point in 2024, followed by rapid expansion into additional tumor categories, including non-small cell lung cancer. Alongside Astellas and Seagen, we reported that the FDA gave accelerated approval to KEYTRUDA combined with enfortumab vedotin, an antibody drug conjugate, for treating adults who have locally advanced or metastatic urothelial carcinoma and cannot receive cisplatin-containing chemotherapy; that accelerated approval came after priority review and rests on data from the KEYNOTE-869 trial; it marks significant progress, since this is the first U.S. approval of a regimen pairing an anti-PD-1 therapy with an antibody drug conjugate for such patients. That approval builds on the success of our foundational efforts studying KEYTRUDA with chemotherapy and offers encouraging proof for pairing immunotherapy with tissue-targeted anticancer agents; we are strongly positioned to extend this effort through a portfolio of next-generation antibody drug conjugates via our partnership with Kelun-Biotech. An expansive global clinical development program is now being planned, and we anticipate starting phase III trials for MK-2870, our TROP2-targeting ADC, both as a monotherapy and alongside KEYTRUDA. We further reported that the FDA has accepted our application for KEYTRUDA plus chemotherapy as first-line treatment for patients who have HER2-negative, locally advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma. That submission is based on data from the phase III KEYNOTE-859 study. During that study, for the individuals involved, giving KEYTRUDA together with chemotherapy produced a significant gain in overall survival, reducing the chance of dying by 22% versus chemotherapy alone, regardless of PD-L1 expression status. A PDUFA action date was established by the agency for December 16th. That opens the door for us to broaden our approval to patients whose disease is HER2-positive, based on KEYNOTE-811. We recently reported positive findings from the phase III NRG-GY018 study, which evaluated KEYTRUDA in combination with chemotherapy as a first-line treatment for patients who have stage III, II-IV, or recurrent endometrial carcinoma. For women facing endometrial cancer, this represents considerable advancement, extending the progress from our approvals in KEYNOTE-146, KEYNOTE-775, and KEYNOTE-158. At the start of this year, the American Cancer Society released its 2023 annual report covering cancer facts and trends. It pointed out that because treatment advances have been lacking, survival for uterine malignancies has not gotten better across the last four decades. We keep working to deliver improved treatment choices in women's cancer. Treating metastatic castrate-resistant prostate cancer is still a major and expanding unmet need, which makes it a field of continuing dedication. From our trials studying KEYTRUDA and LYNPARZA, we have gathered meaningful insights so far, and before this year ends we intend to launch phase III studies of MK-5684, an oral nonsteroidal inhibitor of CYP11A1 that is novel and stems from our partnership with Orion. Additionally, alongside AstraZeneca, we anticipate the conversation about the PROPEL study at the Oncologic Drugs Advisory Committee meeting that is coming up. The advancement we are achieving makes us proud, and we anticipate holding an Investor Event at ASCO in Chicago. Kindly reserve the evening of Monday, June 5th on your calendars, since we will share an update there on our oncology strategy and development program. Now moving to how our infectious disease program is progressing.
Dean Li
executiveRight now, we're actively enrolling several new phase III trials for islatravir taken once a day alongside doravirine, and together with Gilead we've restarted the phase II study of an oral regimen combining islatravir and Gilead's lenacapavir, dosed once weekly; our commitment is to push the science forward so that new HIV treatment options become available. Turning to LAGEVRIO, we keep prioritizing access worldwide when COVID-19 surges occur across the globe, Japan included, where the Ministry of Health, Labour and Welfare just granted full approval for treating COVID-19. Evaluation of LAGEVRIO against other viral respiratory infections is ongoing, and we'll share more once studies read out. Last, regarding the acquisition of Prometheus we announced recently. Prometheus brings a strong scientific pedigree, with a candidate showing exciting potential in ulcerative colitis as well as Crohn's disease. TL1A is a novel target, offering the chance to transform standard of care in a disease area where existing therapies are frequently inadequate and high unmet need persists. Prometheus Biosciences' anti-TL1A antibody, PRA023, is a potential first-in-class late-stage clinical candidate possessing a unique dual mechanism of action, with anti-inflammatory and anti-fibrotic properties. In both ulcerative colitis and Crohn's disease, PRA023's phase II results showed strong efficacy. Moreover, at an interim analysis, data from the biomarker-positive subpopulation pointed to even greater efficacy, with patients more likely to achieve clinical remission. By pairing Prometheus Biosciences' deep understanding of IBD with Merck's deep expertise in developing and implementing biomarkers, we hope to bring about a new era in immunology in which patients are matched to the right therapy through a precision medicine approach. Prometheus' biobank of IBD specimens has produced deep molecular insights that serve as the foundation for discovering PRA052. We look forward to building on that knowledge to gain further insights, which will make it possible to identify and prioritize additional targets. To close, we keep making progress toward our goal of creating innovative medicines that will improve outcomes for patients. Now, I'll hand the call back to Peter.
Peter Dannenbaum
executiveDean, Michelle, thanks — let's move on to questions. Analysts, please keep it to a single question apiece today. Our goal is to wrap up this call by the top of the hour. Thanks.
Robert Cusick
analystHello, I'm Robert Cusick, filling in for Terence. We appreciate you addressing our inquiry. You along with your collaborator, Moderna, are running a phase I basket study involving the PCV. Could you provide more detail about how that trial is structured, and do you currently hold any of the results internally? Thanks.
Dean Li
executiveYes, thanks. Speaking is Dean. I'd prefer to concentrate mainly on the phase III effort we're moving forward with in melanoma, and probably in additional indications too. A basket trial is underway to examine how far tumors respond when a combination of KEYTRUDA alongside a personalized, or individualized, neoantigen therapy is used. Let me offer a broad picture. We possess somewhat of a guide regarding which immune sensitive tumors are located where, and within our basket trial we'd probably give those priority.
Peter Dannenbaum
executiveExcellent. Many thanks. Let's take the following question.
Seamus Fernandez
analystOh, wonderful. I really appreciate you taking my question. What I'd like to ask about is the opportunity with Kelun-Bio. Dean, I was just wondering whether you might bring us up to date. As I recall, it was mentioned before that longer-term data could potentially arrive at some point later in this year. I'm simply curious whether that remains true, or whether the way competitors are behaving has somewhat altered that plan. Perhaps you could also give us a sense of how excited you are about this specific product, and where you think it might stand apart from other offerings within the same category. Many thanks.
Dean Li
executiveMy answer would simply be that the way competition is playing out actually makes us keener to drive our programs with greater effort and speed. On June fifth, at ASCO, we'll be sharing data drawn from what we've gathered across a range of cancers; we'll hold an investor event. I believe it has also already been accepted for a presentation at ASCO itself. That's something we're quite eager about, and we're equally eager about the fact that, as is known, the earliest sign of anti-PD-1 combined with an antibody-drug conjugate, coming out of our work with Seagen, has demonstrated a favorable effect, and we hypothesize this could have wider reach — not confined to a single ADC or a single indication, but extending more broadly across numerous antibody-drug conjugates — and that is why we want to move forward not only the TROP2 ADC, but also a great many other ADCs for which we have yet to share any data.
Peter Dannenbaum
executiveAlright, let's move on to the following inquiry.
Luisa Hector
analystHi there, and thanks for allowing me to ask. I was hoping you might provide an update regarding KEYTRUDA — specifically how it is performing in the adjuvant lung context and how it stacks up positionally versus your rival, plus how a subcutaneous version might alter that picture, whether from the competitor or from you, and when we might see phase III results for your newer subcutaneous form? Thanks.
Dean Li
executiveI'll take the portion about early-stage lung. As we've discussed previously, earlier stages matter a great deal. We have already observed this in Triple-Negative Breast Cancer, in RCC, and in melanoma. My sense is that the opportunity to accomplish this in lung will prove considerable. Once more, regarding our KEYNOTE-671, the initial perioperative study to report a statistically significant and clinically meaningful gain in EFS along with a statistically significant gain in pathologic complete response, those findings will also be shared in June. I'd further stress that event-free survival and overall survival serve as the primary endpoints of our trial. The majority of competitors lack OS as a primary endpoint. I'd also stress that this applies in the perioperative context, yet we have adjuvant as well, so we offer a wide treatment selection when it comes to progressing in the earlier stage; across all earlier stages, be it lung, Triple-N egative Breast Cancer, RCC, or melanoma, I believe it will grow increasingly essential to deliver innovation that lets patients enjoy, so to speak, a more normal capacity to remain on these therapies over the long term — they present a distinct profile compared with a metastatic patient. We think offering alternative routes of administration will matter, and we're pushing forward our subQ pembrolizumab, particularly with hyaluronidase, since that enables us to offer both a Q3 weeks schedule and, crucially, a Q6 weeks schedule as well. That dosing interval, in my view, will matter greatly for patients.
Robert Davis
executiveLuisa, from a commercial standpoint, I'd like to chime in here. You know, the initial launch in lung for KEYNOTE-091 has gotten off to a solid beginning. We're genuinely seeing positive adoption. The issue, as you're aware, is that screening rates overall tend to be lower, so growth is going to take longer than what we witnessed, say, or what we've been observing with Triple-Negative Breast Cancer. Right now, the launch is progressing nicely. Looking ahead, and ideally, once we, you know, potentially get approval for KEYNOTE-671, we'll be the sole company offering both adjuvant and neoadjuvant options, plus clearly a leading position in the metastatic setting. At this point in time, we still view this as a significant opportunity, and over the long term it will keep fueling our growth in lung. Of course, we need to make that happen in the adjuvant setting to achieve this. On the metastatic side, you know, we're maintaining our leadership position.
Peter Dannenbaum
executiveGreat. Thank you, Luisa. Next question, please.
Chris Shibutani
analystThanks a lot. Regarding sotatercept, there's clearly a wide range of possible uses — not only based on what came out of STELLAR, but also in earlier and later lines, where you have Hyperion and Zenith. Could you remind us whether interim readouts might be possible, and if that's the case, what kind of timeline might apply? On a related note, what's your thinking when it comes to your overall strategy in PH and PAH? You now also have assets from Prometheus that could potentially be used in the systemic sclerosis ILD population. There's a great deal of opportunity here, so if you could just help lay out some of the strategic thinking, that would be helpful. Thanks.
Dean Li
executiveYes. I'd prefer to concentrate on pulmonary artery hypertension. I tend to keep that somewhat separate from other types of lung disease. One is primarily vascular, while the other could be described as primarily parenchymal. I tend to treat conditions such as IPF and interstitial lung disease as separate from scleroderma, and distinct from things like pulmonary artery hypertension. You're correct that we believe sotatercept is going to matter. We're moving ahead with sotatercept and STELLAR. We have Zenith and Hyperion. There are interim analyses, though I don't really want to spell out the details, since many of them are event driven. Zenith, as you're well aware, is in a more advanced setting, while Hyperion is really attempting to move it more into the front line; we also think it could potentially change the way people view PAH treatment. For the most part, people have focused on vasodilatation, or dilation. I believe this mechanism — this activin signaling inhibitor — given the way it works, which remodels the tissue, is going to reshape the field. As it reshapes things, it will potentially reshape the dynamics of the vasodilatory pathways; that's why we're so enthusiastic about our in-house sGC program, MK-5475, since we think it could be a very important combination agent alongside other vasodilatory mechanisms that are already approved, as well as in combination with sotatercept.
Peter Dannenbaum
executiveGreat. Thank you, Chris. Next question, please.
Hardik Parikh
analystHello, Hardik Parikh here, dialing in on behalf of Chris Schott. I've got a single question regarding business development. When you take into account the strides the internal pipeline has made, and now with the Prometheus transaction in the picture, do you hold any preference or lean toward earlier-stage versus later-stage BD activity, or toward particular therapeutic fields — oncology, cardiovascular, or perhaps an emerging area within your portfolio?
Robert Davis
executiveYes, well, I'm glad you asked that. Clearly, our perspective on this hasn't shifted at all, even with what you've watched us pursue lately and given the progress you pointed out within our internal pipeline. The starting point is posing this: where is the most convincing science that we believe can be applied to address an unmet need, that carries strategic alignment, and where do we find value matching up? That's the spot we act on. Standing where we are right now, our belief remains that chances exist for us to keep pursuing business development. I'd describe us as extremely happy with how the internal pipeline is advancing. When you examine the therapeutic fields we've been expanding into, clearly these are places where excellent science keeps emerging — oncology, which holds an abundance of scientific work, immunology, plus what we've observed in cardiovascular. What has pulled us toward those therapeutic fields is the scientific promise we've identified. Regarding early versus late, the deciding factor is genuinely how much confidence our scientific group holds in that specific opportunity; we aren't aiming for one instead of the other, though I'll say we still don't hold the view that chasing commercialized products purely to gain revenue is our approach. Our emphasis is on constructing the pipeline, for both the near term and the long term, and we execute deals across the entire spectrum; we mention the acquisitions in the phase II and phase III space, yet we seldom discuss the fact that we're engaging in numerous collaborations and other licensing arrangements at an early phase; we genuinely consider the complete phase of development and will forever be guided by the pipeline. Should it carry a commercial opportunity along with it, wonderful. There will always need to be a pipeline component present for us to want to pursue it.
Peter Dannenbaum
executiveExcellent. Thank you. Let's take our next question.
Carter Gould
analystExcellent. Good morning, and thanks for taking my question. I suppose this one is for Rob and Caroline — I'd really like to hear your most recent thinking regarding the proposed legislation from the EU, and how it might alter the way you approach bringing drugs to market in Europe? And I suppose the implication would extend as well to how you consider potential business development, along with the timing of those revenues and possibly shorter periods of exclusivity? Any perspective there would be useful. Thank you.
Robert Davis
executiveWell, if you take a look at what the EU has just released, clearly the message at a high level is that, taking everything into account, we worry that it keeps placing innovation at a disadvantage within Europe and leaves Europe at a competitive disadvantage when we consider where to put our dollars and where to introduce new products; that being said, when you weigh it all up, certain pieces of what was put forward we actually do back. Certain pieces, in our view, require modification. On the backing side, plainly the reality that some attempt has been made to streamline and update the regulatory system, which could potentially speed up approvals — that was largely something our industry advocated for, and we view it positively. As you note, the piece that offsets that and is quite troubling is the reality that they've cut the data exclusivity period and rendered it mostly conditional on whether you launch throughout the member states, on whether you conduct comparative studies, and on whether you have launches. We have to grasp that. We will keep working to ensure people grasp the consequences that could carry when we consider where we would introduce products, and that's effort we will undertake. There are likely a couple of years before this takes effect, so there's time for us to negotiate. As things stand right now, I wouldn't claim that I see particular consequences for our business development approach. It's more a matter of the broader theme of what amounts to a push against innovation that worries us, since Europe is a significant market. Securing access to our medicines for people across the European Union matters. We want to be present there. We simply must ensure it remains sustainable from a business standpoint.
Peter Dannenbaum
executiveExcellent. Thanks, Carter. Let's take the next one.
Tim Anderson
analystThanks. My question concerns GARDASIL and the Chinese market. The agreement with Zhifei, your distributor in China, was made public roughly two months back, and it indicates very sizable purchase commitments on a steady basis across the coming several years, after which it sort of tapers off and decreases. Taken at face value, that might imply some sort of bolus dynamic at play, meaning the growth curve isn't straight. It rises for a period, then shrinks as you move through patients who had been warehoused. Should we view the longer-term adoption of GARDASIL in that specific market that way — that it may not follow a linear path? Thanks.
Robert Davis
executiveYes. If you simply examine the Zhifei agreement, it's crucial to recognize that the figures stated in that agreement represent minimums. As a matter of fact, we've demonstrated — and our track record shows — that we've actually delivered considerably above those minimum levels. I wouldn't read that as a literal projection for the China business, since there are possibilities tied to broader age groups as we keep increasing penetration within what remains a sizable population with unmet need. There are chances to outperform what that agreement specifies. Assuming the past tells us something about what's ahead, we'd anticipate seeing that progress continue. I would not take that as signaling a downturn for GARDASIL in China across the years to come.
Caroline Litchfield
executiveThe one additional point I'd make is that, when it comes to research, our attention stays on trials taking place in China that back gender-neutral vaccination — something that might represent a strong chance to safeguard additional lives and deliver growth going forward.
Peter Dannenbaum
executiveGreat. Thank you, Tim. Next question, please.
Malcolm Hoffman
analystHi there, this is Malcolm Hoffman, covering for Evan. Here's what we'd like to know: when you factor in the phase III results, the Prometheus transaction, and new assets like the oral PCSK9, do you think the team now has enough in place to produce growth all the way through the KEYTRUDA LOE? Thank you.
Robert Davis
executiveYes. Malcolm, that's one I'll take. To start, I want to say we're feeling very positive about the progress achieved within such a short period. If you look at the opportunity to be set up for growth that lasts well beyond the coming decade, we feel we've taken important steps — including, as you noted, the Acceleron transaction. I'd also highlight our extensive, robust in-house cardiovascular pipeline, which, as you know, we've described as holding eight possible product launches between 2024 and 2028, capable of bringing in over $10 billion by the time we reach the middle of the 2030s. On the oncology side, we've already talked about this: if you take our ADC portfolio plus the many small molecules we acquired through business development — and that leaves out anything from the individualized neoantigen therapy, the program we used to call the personalized cancer vaccine with Moderna, so it's not even part of the figure — we're looking at more than $10 billion of opportunity from those assets over that same period. Today, we've come a long way. I'm not going to say whether I believe we're positioned to grow, and we aren't offering specific guidance. Considering how quickly we've advanced and what we've accomplished in a brief window, plus the schedule ahead of us, the means at our disposal, and what Dean and his group are achieving in the lab, I'd put it this way: 2028 is no longer where my attention is. Instead, my focus is on securing durable expansion far beyond into the following decade.
Peter Dannenbaum
executiveThanks. Let's take the next question.
Andrew Baum
analystThanks. This one's for Dean. Would you be able to discuss the cardiovascular outcome trial that's planned for your oral PCSK9, specifically how you weigh certain historical data that back the notion that how long treatment lasts in a medium trial is tightly linked to efficacy, and that the parentals were likely dosed for a period that was too brief, which implies a longer trial is needed, against the other side of things, the effect of the IRA cutting into returns, at least among the Medicare population in the U.S.? Thank you.
Dean Li
executiveMuch appreciated for posing that. To start, I want to stress that right now we are engaged in ongoing conversations with the regulators concerning our program while we nail down what the phase III trial will look like. That much I'll say openly. My next point is simply this: there's a perspective that's shifting, and I believe the field is still working through it. It isn't merely that LDL serves as a superb biomarker. It isn't merely that PCSK9 constitutes a superb pathway. What matters is that MK-0616 blocks at precisely the same site as certain antibodies do. The way someone reads that, and the way someone reasons about biomarker results in that context, will, I believe, be an ongoing dialogue with the regulators. As for your second question, the historical piece from before — I think what you're getting at is the notion that had those antibody studies run somewhat longer, their effect on outcomes would have been deeper; these are matters we're raising with the regulators as they weigh how a biomarker differs from an outcomes trial. I'd second your stance, namely that going too brief carries the danger of sacrificing the fullest possible effect you could secure on the label. That, as you noted, has to be weighed against whatever the IRA ends up being however many years down the road; those are the trade-offs, yet your read on those other trials matches what we see too, and my broad view is that we ought to push for the greatest effect on patients, since whatever that label turns out to be, it will remain in place permanently.
Peter Dannenbaum
executiveThanks, Andrew. Let's take the next question.
Mara Goldstein
analystOh, excellent. I really appreciate you taking it. I also wanted to ask about the personalized cancer vaccine we're working on with Moderna. After AACR, the response rate in the monotherapy arm — the KEYTRUDA arm — looked low compared with some of the historical benchmarks, from what I could tell. Could you address that, especially given what we've observed for other therapeutics being tested against KEYTRUDA monotherapy comparators?
Dean Li
executiveYeah. Let me begin by saying this is something we always do, and so does everyone else — cross-trial comparison between companies, and also within companies and their own agent. What I'll say is that among the issues raised was that the pembrolizumab monotherapy arm did comparably to KEYNOTE- 054 in the high-risk subgroups, meaning stage IIIC and D; those were also part of KEYNOTE- 942. Broadly speaking, KEYNOTE- 942 involved more advanced disease than KEYNOTE- 054 did. There's a way for us to probabilitize when the stage is the same; we feel very comfortable with the pembrolizumab monotherapy arm in the trial that Merck and Moderna moved forward with. I want to reemphasize once more that for us this is a scientifically important development. This is genuinely the first time I can remember seeing the impact of a personalized, or individualized, neoantigen therapy — or a personalized cancer vaccine — with that profound a readout in a phase II. We're excited to move that into phase III for melanoma and to spool up additional phase III trials, as we look to see how far we can push this strategy.
Peter Dannenbaum
executiveThanks, Mara. Let's take the next question.
Umer Raffat
analystHey, everyone. Dean, regarding TIGIT, it's clear the doublet arm wasn't going to hit PFS, which means the triplet could still have a chance at reaching PFS. What I want to know is, how confident are you about achieving something like at least a 20% benefit on PFS? If that ends up being the case, do you simply hold off until phase III? Would you go to a regulator? I mean, what comes after that, given this is a second-line trial?
Dean Li
executiveSo, I want to stress something here. I believe what you're referring to is the phase II trial, and those phase II studies do give us information. But we've got five phase III trials running right now. What I'd say is that those five phase III trials are what the FDA is going to review — that's the set they'll examine — and we're moving those forward, and not only in metastatic settings. We've got a number of them in lung, but there's another point I'd like to underline, something I've mentioned before. It ties into what's been said regarding KEYNOTE-671; it ties into the question about individualized neoantigen therapy, and it'll tie in here as well. As we consider IO strategies, particularly IO + IO combinations, our focus is increasingly shifting toward earlier stages of disease, for two reasons: it matters enormously for patients, and it's a point where we can truly intervene early, but also we see that as a key area for us to revisit across every one of our IO assets in that earlier stage.
Robert Davis
executiveThanks, Umer. Could we have the next question?
Daina Graybosch
analystHello, and thanks for taking this. This follows up on the last couple of items in your response, Dean. In early-stage melanoma, it appears you plan to run two phase III combination studies at the same time — one adding your TIGIT-vibostolimab, and one adding the individualized neoantigen therapy. Could you explain the rationale for placing two big bets in a single indication, and ought we to anticipate a comparable approach broadly, and for these two particular add-ons in other early-stage indications?
Dean Li
executiveLet me pull back briefly. Our capacity to enter earlier stage cancers only became available perhaps 2 years ago, correct? For combinations to work, it matters greatly that your backbone molecule truly delivers an effect, since that is what lets you assess what each component contributes. We feel quite at ease advancing our IO strategies into earlier stages. We are doing that, as you noted, for both pembro and TIGIT, and also for pembro plus the individualized neoantigen therapy; we have strong confidence that patients' willingness to participate is considerable, and our capacity to enroll and conduct meaningful trials in that setting matters too. I would add that as additional readouts emerge in earlier stage cancer across any of our assets — be it LYNPARZA, be it an ADC, or be it KEYTRUDA — you will probably see us pursue several combinations during those phases.
Peter Dannenbaum
executiveGreat. Thank you, Daina. We're gonna try to get to two more questions, please.
Yihan Li
analystHello, this is Yihan calling in for Colin. We appreciate you fielding our question, and congratulations on the quarter. I have one more question regarding the KEYTRUDA LOE. When it comes to exclusivity, what kind of protective strategy might the subcutaneous formulation of KEYTRUDA provide? Thank you.
Robert Davis
executiveThanks for asking that. When we consider the subcutaneous formulation and the settings where it could be used, it's clearly more centered on situations involving monotherapy as we examine earlier lines of therapy. That's as we keep moving forward our adjuvant and neoadjuvant approach across the various tumor types, and also in cases where we pair KEYTRUDA with small molecules. From what we're seeing, looking ahead, roughly 50% of what we have as KEYTRUDA would be reachable via the subcutaneous route, according to that definition of those areas.
Peter Dannenbaum
executiveExcellent. Thanks. Let's take the last question.
Trung Huynh
analystHey, everyone. This will be brief. With your renewed focus on immunology, I wanted to ask about gefapixant. GSK just acquired a product with a comparable mechanism of action for roughly $2 billion. They described peak sales in the single billion-dollar range. Could you perhaps provide an update on where gefapixant stands following the CRL you received, and what your expectations are for this opportunity?
Dean Li
executiveI'll take that one. As you remember, with gefapixant, we had positive phase III trials. We got a CRL. That CRL has nothing to do with safety or really any major issue that would need another clinical trial. The focus was on how the analysis was performed and how costs were counted. We've submitted additional analysis and will submit additional analysis to the FDA in the first half of this 2023. Broadly, I think the timing is that upon submission of all that data, generally the FDA then readdresses the CRL within six months. It's already approved in Japan and Switzerland. As you mentioned, there's renewed interest given the recent transaction. I don't know if Caroline, would you like to respond to that?
Caroline Litchfield
executiveI'd simply note as well that, at present, this is a group that's greatly lacking in care. Within the United States, 1 in 10 individuals deal with chronic cough, meaning this is a market that has yet to be established. If our efforts with the FDA prove successful, we're eager to introduce a choice that helps patients and generates revenue for our business.
Peter Dannenbaum
executiveExcellent. I appreciate that, Trung, and I appreciate everyone for those really solid questions you asked today. We're eager to hear from all of you and to keep working with you going forward. Many thanks.
Operator
operatorThanks. That wraps up the conference call for today. At this point, you're free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.